BNP Paribas Financial Markets Reduces Position in Merus (NASDAQ:MRUS)

BNP Paribas Financial Markets decreased its position in shares of Merus (NASDAQ:MRUS - Free Report) by 3.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 187,548 shares of the biotechnology company's stock after selling 7,006 shares during the period. BNP Paribas Financial Markets owned 0.27% of Merus worth $7,886,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MRUS. Harbor Capital Advisors Inc. lifted its stake in shares of Merus by 2.2% during the 4th quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company's stock worth $1,817,000 after purchasing an additional 921 shares during the period. Harbour Capital Advisors LLC acquired a new position in Merus in the fourth quarter valued at $360,000. Avior Wealth Management LLC purchased a new position in Merus during the fourth quarter worth about $76,000. KBC Group NV boosted its stake in Merus by 4,583.6% in the 4th quarter. KBC Group NV now owns 57,234 shares of the biotechnology company's stock worth $2,407,000 after buying an additional 56,012 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Merus by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company's stock valued at $610,000 after buying an additional 1,398 shares during the period. Institutional investors and hedge funds own 96.14% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on MRUS. Needham & Company LLC reiterated a "buy" rating and set a $83.00 price objective on shares of Merus in a report on Wednesday, April 9th. Piper Sandler began coverage on shares of Merus in a research note on Thursday, February 13th. They set an "overweight" rating and a $84.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $85.00 price objective on shares of Merus in a research note on Monday, March 3rd. Wells Fargo & Company dropped their price objective on Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Finally, Bank of America reduced their target price on Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $85.15.

Merus Stock Performance

Shares of MRUS stock traded down $0.32 during trading hours on Thursday, reaching $40.08. The company had a trading volume of 753,631 shares, compared to its average volume of 718,614. The company has a market capitalization of $2.77 billion, a P/E ratio of -10.15 and a beta of 0.94. Merus has a twelve month low of $33.19 and a twelve month high of $61.61. The stock's fifty day simple moving average is $43.21 and its 200 day simple moving average is $43.92.

Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, equities analysts expect that Merus will post -3.85 earnings per share for the current year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.